Ipratropium Bromide for Exercise-Induced Laryngeal Obstruction

This trial examines whether ipratropium bromide can aid kids and teens with Exercise-Induced Laryngeal Obstruction (EILO) who experience breathing difficulties during exercise. Researchers aim to determine if this treatment reduces breathlessness and improves exercise capability compared to a placebo. The trial will test the treatment in two sequences: some participants will receive ipratropium bromide first, followed by a placebo, while others will receive the placebo first, followed by ipratropium bromide. Kids and teens diagnosed with EILO who frequently experience shortness of breath during exercise may be suitable candidates for this trial. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group.

If you are taking anticholinergic medications, you will need to pause them for 24 hours before participating in the trial.

Research has shown that ipratropium bromide is generally safe for use. The FDA has already approved it for other conditions, such as chronic obstructive pulmonary disease (COPD), indicating a strong safety record. In studies on exercise-induced laryngeal obstruction (EILO), participants experienced few serious side effects. Some mild effects, like dry mouth or a slight cough, were noted, which are common with inhaled medications and usually resolve quickly.

Ipratropium Bromide is unique because it targets the underlying muscle contractions in the throat that cause exercise-induced laryngeal obstruction (EILO). Most current treatments for EILO focus on managing symptoms, such as using breathing techniques or medications that reduce inflammation. However, Ipratropium Bromide works by directly relaxing the airway muscles, potentially offering quicker and more direct relief. Researchers are excited about this treatment because it could provide a more efficient and targeted approach to easing the breathing difficulties associated with EILO, improving the quality of life for those affected by this condition.

Research suggests that ipratropium bromide, a medication that blocks certain signals in the throat, might help with symptoms of exercise-induced laryngeal obstruction (EILO). However, some studies have shown it did not improve breathing problems or exercise performance in people with EILO. Conversely, a report on a few cases showed symptom improvement when ipratropium bromide was used before exercise. This trial will compare the effects of ipratropium bromide with a placebo to determine its effectiveness for EILO. This mixed evidence indicates that while it might help some people, its overall effectiveness for EILO remains unclear. More research is needed to determine how well it works for this condition.²⁴⁵⁶⁷